Preclinical Activity With Olaratumab in Sarcoma

Video

Caitlin May, PhD, postdoctoral research scientist at Eli Lilly and Company, discusses preclinical activity with olaratumab (Lynparza) in pediatric sarcoma models.

Caitlin May, PhD, postdoctoral research scientist at Eli Lilly and Company, discusses preclinical activity with olaratumab (Lartruvo) in pediatric sarcoma models.

Olaratumab is a human anti-PDGFRα monoclonal antibody that was previously found to have activity in adult patients with sarcoma, May explains. However, recent research suggests that there are several subtypes of pediatric bone and soft tissue sarcoma that express high levels of this receptor. These findings suggest that there is preclinical activity of olaratumab in pediatric mouse models and cell lines.

A phase Ib clinical trial is enrolling pediatric patients with sarcoma to receive olaratumab in combination with chemotherapy agents, which is scheduled to be completed in 2019, she adds.. Currently, olaratumab's approved indication by the FDA is in combination with doxorubicin for adult patients with advanced soft tissue sarcoma.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD